These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 10215647)

  • 1. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
    Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
    J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis.
    Takano T; Cybulsky AV; Cupples WA; Ajikobi DO; Papillon J; Aoudjit L
    J Pharmacol Exp Ther; 2003 Apr; 305(1):240-9. PubMed ID: 12649375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
    Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
    Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
    Rossat J; Maillard M; Nussberger J; Brunner HR; Burnier M
    Clin Pharmacol Ther; 1999 Jul; 66(1):76-84. PubMed ID: 10430112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.
    Nüsing RM; Reinalter SC; Peters M; Kömhoff M; Seyberth HW
    Clin Pharmacol Ther; 2001 Oct; 70(4):384-90. PubMed ID: 11673754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
    Tuleja E; Mejza F; Cmiel A; Szczeklik A
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1111-5. PubMed ID: 12730088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
    Kato S; Ogawa Y; Kanatsu K; Okayama M; Watanabe T; Arakawa T; Takeuchi K
    J Pharmacol Exp Ther; 2002 Nov; 303(2):503-9. PubMed ID: 12388629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats.
    Turull A; Piera C; Queralt J
    Inflammation; 2001 Apr; 25(2):119-28. PubMed ID: 11321358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
    Praticò D; Tillmann C; Zhang ZB; Li H; FitzGerald GA
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3358-63. PubMed ID: 11248083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
    Ehrich EW; Dallob A; De Lepeleire I; Van Hecken A; Riendeau D; Yuan W; Porras A; Wittreich J; Seibold JR; De Schepper P; Mehlisch DR; Gertz BJ
    Clin Pharmacol Ther; 1999 Mar; 65(3):336-47. PubMed ID: 10096266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
    Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial.
    Leese PT; Recker DP; Kent JD
    J Clin Pharmacol; 2003 May; 43(5):504-13. PubMed ID: 12751271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine.
    Llinás MT; López R; Rodríguez F; Roig F; Salazar FJ
    Am J Physiol Renal Physiol; 2001 Nov; 281(5):F975-82. PubMed ID: 11592955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
    Swan SK; Rudy DW; Lasseter KC; Ryan CF; Buechel KL; Lambrecht LJ; Pinto MB; Dilzer SC; Obrda O; Sundblad KJ; Gumbs CP; Ebel DL; Quan H; Larson PJ; Schwartz JI; Musliner TA; Gertz BJ; Brater DC; Yao SL
    Ann Intern Med; 2000 Jul; 133(1):1-9. PubMed ID: 10877734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
    J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.